Navigation Links
Neurogenetic studies show proprietary compound reduces brain plaques linked to Alzheimer's
Date:9/9/2010

SAN DIEGO -- In the Sept 9, 2010 issue of Neuron, Neurogenetic Pharmaceuticals, Inc. (NGP) reports proof of concept studies that show its proprietary compound, NGP 555, is effective in preventing the amyloid pathology of Alzheimer's disease (AD) in a transgenic mouse model. The study further demonstrates that following chronic treatment with the gamma secretase modulator (GSM) compound from NGP, the mice were devoid of gastrointestinal side effects, an adverse finding commonly associated with gamma secretase inhibitors (GSIs).

A major pathological hallmark of Alzheimer's disease is an abundance of neuritic plaques in key areas of the brain involved in memory and cognition. Decades of studies have confirmed that Aβ42 forms the "seed" of these amyloid plaques, which gradually accumulate in the brain and induce neuronal cell death in the underlying brain tissue. This "toxic" molecule is generated by a stepwise process involving a pivotal enzyme, gamma secretase. Modification of gamma secretase activity to decrease production of Aβ42, thereby reducing the deposits of Aβ42 -seeded plaques, would be beneficial for the prevention of Alzheimer's disease-related pathology.

"We are pleased to make public these data on our gamma secretase modulator, NGP 555," said Dr. William T. Comer, President and CEO of Neurogenetic Pharmaceuticals. "Deposition of amyloid plaques can precede dementia by many years, and the progression of plaques to dementia reflects neuronal loss which is irreversible. We believe that halting this gradual progression of AD from pathology to dementia represents a major unmet need, especially given the growth of an aging population and the enormous cost to society for care and hospitalization. Recent advances in the use of A biomarkers in the cerebrospinal fluid and brain scans should permit early diagnosis of AD pathology and allow us to show that NGP 555 prevents the amyloid pathology."

T
'/>"/>

Contact: Tom Gable
tom@gablepr.com
877-251-3888
Gable PR
Source:Eurekalert

Page: 1 2

Related biology technology :

1. Health Robotics Releases Results of First 20 i.v.STATIONs Return On Investment (ROI) Studies in the USA and Canada
2. New hydrolysis model promising tool in cellulosic biofuel studies
3. Stretching single molecules allows precision studies of interacting electrons
4. Genomic Health Presents Six New Studies Including Four Oral Presentations in Breast, Colon and Renal Cancers at American Society of Clinical Oncology (ASCO) Annual Meeting
5. Agendia Presents Broad Array of Predictive and Prognostic Studies on Breast and Colorectal Cancers at ASCO 2010 Annual Meeting
6. Advanced Phase I and Phase II Studies of Targeted Gene Delivery Confirm That Rexin-G Impacts Survival in Chemotherapy-resistant Bone and Soft Tissue Sarcoma (ASCO 2010)
7. Studies Demonstrate Early Stage Detection and Economic Benefits of a Blood-Based Test for Lung Cancer
8. Tumor-Targeted Rexin-G Prolongs Survival in Gemcitabine-Resistant Metastatic Pancreas Cancer in Advanced Phase I and II Studies (ASCO 2010)
9. Lilly Oncology to Unveil More Than 50 Studies at ASCO 2010
10. Encorium Group, Inc. Announces New Business Contract Wins of $6.8 Million, Including Two Pivotal Phase III Studies for a Major Asian Technology Company
11. Epeius Biotechnologies Reports Major Clinical Advances: Noteworthy Clinical Case Studies in Cancer Gene Therapy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... The report expects global cell isolation ... It also provides a carefully analyzed data about the ... the market. , Full Copy of Report @ ... market for cell expansion will keep witnessing growth at ... growth to be driven by rapid technological advancements, government ...
(Date:12/24/2014)... China Biologic Products, Inc. (NASDAQ: CBPO, ... integrated plasma-based biopharmaceutical company in China ... Shandong Taibang Biological Products Co. Ltd., has received ... Food and Drug Administration (the "CFDA") for its ... in the Company,s public filings, the CFDA inspected ...
(Date:12/24/2014)... , December 23, 2014 ... Algeria , out today and available for free download ... actors driving change and growth in the sector today. ... scored notable successes has been in developing a homegrown pharmaceutical ... percent local production still remains some way off. A cursory ...
(Date:12/24/2014)... , Dec. 23, 2014  Rock Creek Pharmaceuticals, ... it has filed a Clinical Trial Application (CTA) with ... products Regulatory Agency (MHRA) seeking regulatory approval to initiate ... molecule, Anatabine Citrate. Contingent on the Company ... a Phase I trial to assess the safety, tolerability ...
Breaking Biology Technology:The Cell Expansion Market is Expected to Reach $14.8 billion by 2019 - New Research Report by MarketsandMarkets 2The Cell Expansion Market is Expected to Reach $14.8 billion by 2019 - New Research Report by MarketsandMarkets 3China Biologic Receives GMP Certification for New Coagulation Factor Facility 2China Biologic Receives GMP Certification for New Coagulation Factor Facility 3PharmaBoardroom Releases New Algeria Pharmaceuticals Report 2PharmaBoardroom Releases New Algeria Pharmaceuticals Report 3Rock Creek Pharmaceuticals Files Clinical Trial Application in the UK for Clinical Trials of Anatabine Citrate Formulations 2Rock Creek Pharmaceuticals Files Clinical Trial Application in the UK for Clinical Trials of Anatabine Citrate Formulations 3
... Osteotech, Inc.,(Nasdaq: OSTE ), a leader ... medicine, announced today that the United States Patent ... U.S. Patent No.,5,676,146. The ,146 patent covers mixtures ... a radiopaque material, such as nondemineralized,or partially demineralized ...
... and biotechnology research companies invested a record $58.8,billion ... new life-changing,medicines and vaccines -- an increase of ... the Pharmaceutical Research and Manufacturers of,America (PhRMA) and ... coincides,with PhRMA,s 50th anniversary, which it observes today., ...
... China,s State Food and Drug,Administration has approved ... confocal microscope in the Peoples Republic of ... Rochester, New York-based medical device and,information company ... Lucid,s VivaScope(R) reflective confocal microscopes (RCM) ...
Cached Biology Technology:U.S. Patent Office Confirms Validity of Osteotech's U.S. Patent No. 5,676,146 2R&D Spending by U.S. Biopharmaceutical Companies Reaches Record $58.8 Billion in 2007 2R&D Spending by U.S. Biopharmaceutical Companies Reaches Record $58.8 Billion in 2007 3Lucid's VivaScope(R) Reflective Confocal Microscope Approved for Sale in China 2Lucid's VivaScope(R) Reflective Confocal Microscope Approved for Sale in China 3
(Date:12/24/2014)... YORK , Dec. 23, 2014  Since its launch ... helped thousands of people to eliminate the pain of ... the antiquated system with their own biometrics fused to ... remember usernames and passwords, Hoyos Labs , the ... announced today that it is offering the app for ...
(Date:12/22/2014)... 22, 2014  NXT-ID, Inc. (NASDAQ: NXTD ... authentication company focused on the growing mobile commerce market, ... consultant, Apollo Robbins for the 2015 International ... Apollo Robbins will be at ... 2015, demonstrating some of his famous theft techniques to ...
(Date:12/22/2014)... Research and Markets ( ... the "The Global Watermarking and Fingerprinting ... http://photos.prnewswire.com/prnh/20130307/600769 ... the global digital media watermarking and fingerprinting ... piracy by securely and invisibly embedding identifiable ...
Breaking Biology News(10 mins):1U Offers Best Solution to the Username / Password Dilemma: For FREE! 21U Offers Best Solution to the Username / Password Dilemma: For FREE! 3NXT-ID Hires Master Pickpocket and Security Consultant Apollo Robbins for Wocket Smart Wallet CES 2015 Debut 2NXT-ID Hires Master Pickpocket and Security Consultant Apollo Robbins for Wocket Smart Wallet CES 2015 Debut 3NXT-ID Hires Master Pickpocket and Security Consultant Apollo Robbins for Wocket Smart Wallet CES 2015 Debut 4The Global Watermarking and Fingerprinting Markets 2
... , Bremerhaven, 19 September 2011. Earth warming will presumably ... the South Pacific Ocean. This is the conclusion drawn ... 50-million-year-old clam shells and wood from the Antarctic. The ... also a climate rhythm over the South Pacific during ...
... Taiwan have confirmed a bidirectional relation between schizophrenia and ... a journal of the International League Against Epilepsy (ILAE), ... more likely to develop schizophrenia and those with schizophrenia ... epilepsy. Prior clinical studies have shown a ...
... have shown, for the first time in an animal, that ... parts of the central nervous system. , They subjected rainbow ... a whitening agent in many products including paints, some personal ... industry. They found that the particles caused vacuoles (holes) to ...
Cached Biology News:50-million-year-old clam shells provide indications of future of El Nino phenomenon 2Study finds bidirectional relationship between schizophrenia and epilepsy 2
... Variable Speed Rocker, with 12" x 14" table; ... x 14" table; 220V. The VSR-50 Variable ... for any lab. The VSR-50 provides a rhythmic ... a gentle to vigourous movement. This makes it ...
...
...
...
Biology Products: